CABA — Cabaletta Bio, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1759138 ·
Last close
$1.02
Market Cap
$220.03M
52W High
$4.23
52W Low
$0.98
ADV30
4,747,691
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -54,707,000 -53,053,000 336,491,000 299,383,000 52,572,000
Jun 2026 0 — -52,021,000 -51,018,000 256,728,000 225,101,000 46,135,000
Mar 2026 0 — -44,296,000 -43,515,000 148,146,000 116,635,000 44,841,000
Dec 2025 0 — -42,611,000 -41,919,000 165,083,000 82,982,000 53,032,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-162,162,000
Investing CF
$100,613,000
Financing CF
$300,772,000
CapEx
$-1,229,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.45
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-664,543,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-187,286,000
Pretax Income TTM
$-189,505,000
Interest Exp TTM
$2,219,000
Analysts
8

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -172,241,000 -167,856,000 165,083,000 53,032,000 112,051,000 -131,080,000
Dec 2024 0 -125,141,000 -115,864,000 185,046,000 32,711,000 152,335,000 -88,222,000
Dec 2023 0 -74,660,000 -67,675,000 253,650,000 17,452,000 236,198,000 -53,549,000
Dec 2022 0 -54,139,000 -52,975,000 116,968,000 12,448,000 104,520,000 -46,380,000

TTM Snapshot

Revenues TTM
$5,814,000
NetIncome TTM
$-181,318,000
OpCashFlow TTM
—
Assets (Latest)
$256,728,000
Forward EPS
$-1.19

Max Pain — expiry 2027-01-15

max pain strike: $1.50 · spot: $1.05 · call oi: 9,264 · put oi: 349
Expected Move to 2027-01-15: ±$0.40 (37.91%) — implied range $0.65 – $1.46 · ATM straddle on $1.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PROK PROKIDNEY CORP. $229.87M $1.10 —
LXEO Lexeo Therapeutics, Inc. $234.24M $2.86 —
LCTX Lineage Cell Therapeutics, Inc. $206.36M $0.82 —
PLX Protalix BioTherapeutics, Inc. $242.84M $2.88 —
DTIL PRECISION BIOSCIENCES INC $196.95M $7.05 —

News headlines (Yahoo Finance, 1h cache)

Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases
2026-11-08 15:00 · Yahoo
Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-05 12:30 · Yahoo
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-04 21:01 · Yahoo
Cabaletta Bio to Participate in Upcoming Investor Conferences
2026-11-03 13:00 · Yahoo
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
2026-05-18 16:00 · Yahoo
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases
2026-06-07 17:58 · Yahoo
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-14 11:05 · Yahoo
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
2026-05-20 13:40 · Yahoo
Pemphigus Vulgaris Market Analysis Report 2026-2036, Profiles of F. Hoffmann La Roche, Argenx, Sanofi, Syntimmune, Allmiral, Cabaletta Bio, and Novartis
2026-05-21 11:42 · Yahoo
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
2026-06-03 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.